Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
759.53-
QQQ
710.980.89%
BTC/USD
76491.000.3717%
DIA
518.520.64%
GLD
395.691.01%
TLT
81.19-

Cabaletta Bio Inc

CABANASDAQ
Trade with Public
Trade with Public
$2.49
-0.10-4.05%
At close: Sep 15, 5:00 PM EST
$2.54
-0.055-2.12%
Pre-Market: 4:09 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Cabaletta Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cabaletta Bio (CABA).

Price Target Range — 13 Quarters

Analyst Consensus — 9 Analysts

8Buy
1Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+683.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026HC Wainwright & Co.Douglas TsaoMaintainedBuy$16
Aug 14, 2026Wells FargoDerek ArchilaPT CutEqual-Weight$4→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved